华北制药
(600812)
| 流通市值：105.52亿 | | | 总市值：105.52亿 |
| 流通股本：17.16亿 | | | 总股本：17.16亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,574,254,051.92 | 9,869,575,819.11 | 7,560,235,670.39 | 5,231,120,589.63 |
| 营业收入 | 2,574,254,051.92 | 9,869,575,819.11 | 7,560,235,670.39 | 5,231,120,589.63 |
| 二、营业总成本 | 2,469,225,602.07 | 9,602,162,210.85 | 7,395,586,299.65 | 5,114,906,965.24 |
| 营业成本 | 1,816,338,278.92 | 6,714,658,593.44 | 5,272,198,266.78 | 3,667,113,196.03 |
| 税金及附加 | 26,799,221.61 | 109,275,550.51 | 77,366,304.85 | 51,943,396.65 |
| 销售费用 | 321,958,401.87 | 1,433,292,527.42 | 1,052,291,747.95 | 744,354,390.35 |
| 管理费用 | 134,047,050.91 | 581,885,940.9 | 415,243,846.33 | 270,489,581.4 |
| 研发费用 | 80,967,533.71 | 337,275,440.94 | 251,674,097.83 | 160,550,724.6 |
| 财务费用 | 89,115,115.05 | 425,774,157.64 | 326,812,035.91 | 220,455,676.21 |
| 其中:利息费用 | 97,396,371.32 | 458,698,019.11 | 345,915,986.61 | 238,700,837.64 |
| 其中:利息收入 | 6,554,100.01 | 25,255,785.32 | 18,449,560.56 | 12,113,598.68 |
| 加:投资收益 | 7,596,720.83 | 46,164,658.18 | 33,415,822.41 | 22,288,412.5 |
| 资产处置收益 | 4,253.94 | 444,156.56 | 440,884.14 | 438,809.62 |
| 资产减值损失(新) | 6,614,126.09 | -16,374,073.77 | 8,350,790.94 | 10,531,887.26 |
| 信用减值损失(新) | -21,594,563.99 | -22,675,856 | -6,417,154.9 | -19,387,968.62 |
| 其他收益 | 5,266,449.31 | 36,708,667.71 | 22,655,374.24 | 17,502,377.05 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 102,915,436.03 | 311,681,160.94 | 223,095,087.57 | 147,587,142.2 |
| 加:营业外收入 | 375,653.51 | 6,936,839.19 | 3,339,164.23 | 3,000,388.63 |
| 减:营业外支出 | 138,827.07 | 8,785,487.37 | 3,458,318.97 | 579,105.16 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 103,152,262.47 | 309,832,512.76 | 222,975,932.83 | 150,008,425.67 |
| 减:所得税费用 | 26,526,600.48 | 94,865,994.43 | 76,535,187.12 | 52,512,865.99 |
| 六、净利润 | 76,625,661.99 | 214,966,518.33 | 146,440,745.71 | 97,495,559.68 |
| 持续经营净利润 | 76,625,661.99 | 214,966,518.33 | 146,440,745.71 | 97,495,559.68 |
| 归属于母公司股东的净利润 | 57,491,586.04 | 126,992,370.2 | 102,463,641.21 | 71,984,395.89 |
| 少数股东损益 | 19,134,075.95 | 87,974,148.13 | 43,977,104.5 | 25,511,163.79 |
| (一)基本每股收益 | 0.03 | 0.07 | 0.06 | 0.04 |
| (二)稀释每股收益 | 0.03 | 0.07 | 0.06 | 0.04 |
| 八、其他综合收益 | 39,722.88 | 1,601,601.48 | -150,201.56 | 792,338.49 |
| 归属于母公司股东的其他综合收益 | 39,722.88 | 1,601,601.48 | -150,201.56 | 792,338.49 |
| 九、综合收益总额 | 76,665,384.87 | 216,568,119.81 | 146,290,544.15 | 98,287,898.17 |
| 归属于母公司股东的综合收益总额 | 57,531,308.92 | 128,593,971.68 | 102,313,439.65 | 72,776,734.38 |
| 归属于少数股东的综合收益总额 | 19,134,075.95 | 87,974,148.13 | 43,977,104.5 | 25,511,163.79 |
| 公告日期 | 2025-04-24 | 2025-03-28 | 2024-10-26 | 2024-08-14 |
| 审计意见(境内) | | 标准无保留意见 | | |